LncRNA MEG3 expressed abnormally in various cancers including breast cancer, but no studies reported the correlation between MEG3 SNPs and breast cancer susceptibility.
Introduction
Breast cancer (BC) is a serious threat to women's health. According to Global cancer statistics 2018[1], there will be an estimated 2.1 million new BC cases and 630 thousand BC related death in 2018. For females, BC is the most common diagnosed cancer (24.2% of the total cases) and the leading cause of cancer death (15.0% of the total cancer death). Although epidemiological studies have identified several risk factors that may be involved in BC, such as age, hormonal state, and family history [2] , the pathogenesis of BC is still unclear. BC is a complex and genetically heterogeneous disease in which genetic changes such as abnormal amplification of oncogenes, or deletion/mutation of tumor suppressor genes, play a substantial role.
Maternally expressed gene 3 (MEG3) is an imprinted gene located at chromosome 14q32.3 in humans, encoding a long non-coding RNA (lncRNA) belonging to the imprinted DLK1-MEG3 regions [3] . This region contains at least three paternally expressed protein coding genes and numerous maternally expressed noncoding RNAs [4] . The imprinted expression of these genes was related to cell development and growth [5] , and experiments in vitro indicated MEG3 can suppress the proliferation of human cancer cells lines [6] .
Researchers found loss of MEG3 related to a variety of human cancers, such as gastric [7] , cervical [8] , and breast [9] cancer. MEG3 can inhibit the occurrence of tumor through various mechanisms. Firstly, MEG3 can inhibit the proliferation of tumor cells and consequently induce apoptosis, which has been confirmed by in vitro experiments and animal models [10] . Secondly, MEG3 plays a role in epigenetic regulation and can alter the function of cancer cells by affecting DNA methylation and regulating the functions of snoRNA and miRNA [11, 12] . Moreover, MEG3 is involved in the regulation of many tumorrelated signaling pathways, including the classic p53, MDM2, and pRb pathway [13] .
The genetic variants may influence the expression or function of MEG3 and consequently alter cancer susceptibility. However, there are no investigation to explore the relationship between MEG3 polymorphisms and breast cancer. In this study, we genotyped three polymorphisms (rs3087918, rs11160608 rs7158663) in MEG3 gene based on 434 BC patients and 700 healthy controls, to explore their relationship with breast cancer.
Materials And Methods

Study subjects
In total, 1134 females were recruited for this population-based case-control study. Among these, 434 breast cancers were enrolled in the Department of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, from 2013 to 2015. 700 healthy females were randomly recruited from medical center of the same hospital during the same period. All BC patients were diagnosed by pathology and detailed immunohistochemical analysis. BC patients who had a history of other malignant diseases or receiving chemotherapy or radiotherapy were excluded. The controls were matched to cases by age (± 2 years) and had no history of malignant tumors, no history of chemoradiotherapy, no obvious abnormality in blood routine examination. The protocol of this study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University Shaanxi Province (Xi'an, China). All patients gave written informed consent prior to participation in the study.
SNP selection and Genotyping
SNPs were selected according to NCBI database and literature. First, the minor allele frequency (MAF) was no less than 0.05 among Asian population. Secondly, the detection rate is less than 95%. Thirdly, The genotype distribution of the three polymorphisms in control groups accorded with Hardy-Weinberg Equilibrium (HWE). Peripheral blood samples were collected in EDTA-coated tubes and conserved at -80℃. Genome DNA were extracted from whole blood samples using ComWin BloodGen Mini Kit (QIAGEN, China, Beijing). Ultraviolet spectrophotometer (Nanodrop, Thermo Scientific, Waltham, MA) was utilized to measure the purity and concentration of extracted DNA. We designed multiplexed SNP MassEXTEND assay using Sequenom MassARRAY Assay Design 3.0 software. DNA samples were genotyped by Sequenom MassARRAY RS1000 according to the standard protocol. The primers applied for the three SNPs were shown in supplemental table S1.
Statistical analysis
The HWE of the three SNPs were calculated using Fisher's exact test in controls group.
Student's t test was adopted to evaluated the difference of age distribution and body mass index (BMI) between BC patients and healthy controls. Two-sided Pearson's chisquare tests were applied to access the differences in the categorical variables between cases and controls, such as age ( < = 49 and > 49), BMI, menstrual-status, and allelic frequencies. P < 0.05 was considered statistically significant. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression analysis. 
Function prediction based on databases
We used RNAfold (http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAfold.cgi) and
LncRNASNP2 (http://bioinfo.life.hust.edu.cn/lncRNASNP/) database to predict the effect of SNP on MEG3. RNAfold is a classic database to predict RNAs structure. Free energy represents the amount of energy that needs to be injected to change the structure. The smaller the corresponding value is, the more stable the structure will be. LncRNASNP2 is a novel database containing 7260238 SNPs on 141353 human lncRNA transcripts and the potential function of the MEG3 polymorphisms.
Results
Demographical and clinical information of study population
This study contained 434 BC cases and 700 healthy control. All the subjects were Han Chinses women from northwest China. There were no statistically significant differences in age distribution, BMI and menopausal status between the patients and the control group.
The detail demographical and clinical information was display in Table 1 . BMI was a statistical index to estimate the body fat in people of any age. In this study, BMI was divided into four levels (underweight, normal weight, overweight, and obese) based on Chinese reference standard. The associations between M E G 3 S N P s a n d B C r i s k Three SNP locus of MEG3 (rs3087918, rs11160608 rs7158663) were genotyped in all recruited subjects, and their respond rate were 99.1%, 99.2% and 99.4%, respectively. HWE (rs11160608: P HWE = 0.844; rs3087918: P HWE = 0.968; rs7158663: P HWE = 0.334.
We didn't find statistical significance for rs11160608, rs7158663 and breast cancer (P > 0.05 in all genetic models). Pooled analysis indicated that rs3087918 was related to a decreased risk of breast cancer [GG vs. TT: OR (95%CI) = 0.67(0.45-0.99), P = 0.042; GG vs. TT + TG: OR (95% CI) = 0.69(0.48 0.99), P = 0.046]. The detail results were showed in Table 2 . Table S2 ). Rs3087918 was related to a reduced susceptibility for women aged 49 and above [GG vs. TT: OR(95%CI) = 0.40(0.22-0.73), P = 0.02] (Table 3) . 
Relationship between MEG3 rs3087918 and clinical characteristics of BC
To further explore the effect of rs3087918 loci and clinicopathological information on BC susceptibility, correlation analysis was conducted in the cases group defined by age, BMI, menopausal status, tumor size, metastasis, clinical stage, ER/PR status and Her-2. As showed in Table 4 , GG and TG + GG genotypes had an increased trend when Her-2 expressed positive [GG vs. TT: OR(95%CI) = 2.37(1.24-4.63), P = 0.010; TG + GG vs. TT: OR(95%CI) = 1.50(1.01-2.24), P = 0.045]. We further divided the cases into luminal, Her-2 and triple negative breast cancer (TNBC) groups according to molecular classification.
However, we found no association between three SNPs of MEG3 and the different molecular typing states of BC (Table S3 ). Table 5 ).
The order of the three SNPs was rs3087918, rs11160608 rs7158663. The order of the three SNPs was rs3087918, rs11160608 rs7158663. Haplotypes with frequency less than 0.03 were excluded. OR: odds ratio; CI: confidence interval.
The function prediction of the rs3087918 in MEG3
LncRNASNP2 (http://bioinfo.life.hust.edu.cn/lncRNASNP/) database to predict the potential function of rs3078918. The centroid secondary structure of rs3087918 was shown in Table S3 and Figure S1 ).
Discussion
The occurrence of breast cancer is a result of a long-term complex interaction between individual genetic background and environmental exposure factors. As the most common type of genetic mutation, SNP is of great significance for breast cancer risk, diagnosis, individualized treatment and prognosis prediction. This study is aimed to investigate the association between MEG3 polymorphisms (rs3087918, rs11160608 rs7158663) and breast cancer. Our study recruited 1134 subjects containing 434 breast cancer patients and 700 healthy controls. The results indicated that the mutant homozygous GG of rs3087918 may associated with a decreased risk of BC, especially in females age < = 49. Comparison between case groups showed genotype GG and TG/GG of rs3087918 were correlated with her-2 receptor expression. The results of haplotype analysis for MEG3 showed that compared with wild haploid TAG, TCG haplotype may increase the risk of breast cancer, while other haplotypes were not significantly correlated with breast cancer risk.
Furthermore, we found rs3087918 may influence the secondary structure of MEG3 and affect the bind of MEG3 to some miRNAs.
Previous evidences showed that MEG3 was highly expressed in normal tissues such as brain, pituitary, placenta and adrenal gland, and its transcripts can be detected in several human organs including ovary, testes, spleen, pancreas, liver, and mammary gland [4] .
However, the expression of MEG3 was lower in various human tumors compared with that in normal human tissues, including breast cancer [15] . MEG3 was recognized as a tumor suppressor deponed on recent researches. In vitro experiments showed that restoring the expression of MEG3 could inhibit cancer cells proliferation and induce their apoptosis [16] , and a similar tumor inhibition effect was found in nude mice [13] . MEG3 can also participant in epigenetic regulation of transcripts in the MEG3 region, such as DNA methylation [17, 18] , snoRNA/microRNA regulation [19] [20] [21] [22] . We used a database named [23] . Downregulation of has-miR-139-3p could induce cancer cell migration and invasion [24] [25] [26] , and a pooled analysis proved that high has-miR-139-3p expression was related to a better prognosis for hepatocellular carcinoma [27] . Thus, has-miR-139-3p was attributed as a tumor suppressor. Hsa-miR-5091 was also reported as a biomarker with better prognosis for pancreatic ductal adenocarcinoma [28] . These were coincident with our results that rs3087918 was related to a decreased risk of breast cancer.
To be best of our knowledge, this is the first study to explore the association between MEG3 SNPs (rs3087918, rs11160608 rs7158663) and breast cancer risk. We used scientific methods and designs and finally obtained credible results. However, there are still some potential limitation should to be clarify. First, we failed to consider the potential influence of environmental, lifestyle and other unknow risk factors on our study. Secondly, this is a one center case-control study with a small samples scale, we should not ignore the selective bias. In the future, more complete and larger sample scale study need to accomplish.
Conclusion
The wild-type homozygous GG of MEG3 rs3087918 was associated with a decreased risk of breast cancer. MEG3 haplotype TCG (SNP sequence: rs3087918, rs11160608, rs7158663) may increase the risk of breast cancer. And the protest effect of rs3087918 on breast cancer may owe to its effect on the structure and function for MEG3.
Supplemental Attachments Figure S1 . The prediction results of s3087918 affect the bind of MEG3 to miRNAs. (A) rs3087918 caused has-miR1203 target gain; (B) rs3087918 caused has-miR-139-3p target loss; (C) rs3087918 caused has-miR-5091 target loss. Table S1 . Primers used for this study. Table S2 . Stratified Analysis of rs11160608 and rs7158663 by age, BMI and menopausal status. Table S3 . Association analysis between three SNPs inMEG3 and Molecular typing of breast cancer. Table S4 . Rs3087918 influence MEG3 binding to miRNAs based on LncRNASNP2 database. Figure 1 he RNAfold algorithm in silico predicting the impact of rs3087918. MFE: minimum free energy.
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